Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas

Blood Cancer Journal

Volumn 5, Issue 10, 2015, Pages

  Lunning, M A ^a   Green, M R ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE ACETYLTRANSFERASE; HISTONE H3; HISTONE METHYLTRANSFERASE; CHROMATIN; HISTONE LYSINE METHYLTRANSFERASE; NUCLEAR PROTEIN;

B CELL LYMPHOMA; CHROMATIN; CHROMATIN STRUCTURE; ENZYME REGULATION; GENE MUTATION; GERMINAL CENTER; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; NUCLEOSOME; PROTEIN PROCESSING; REVIEW; ANIMAL; DIFFUSE LARGE B CELL LYMPHOMA; GENETICS; MUTATION; PATHOLOGY;

ANIMALS; CHROMATIN; GERMINAL CENTER; HISTONE ACETYLTRANSFERASES; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MUTATION; NUCLEAR PROTEINS;

EID: 84989316716     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2015.89     Document Type: Review

References (85)

1. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005; 5: 251-262.
2. Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2002; 2: 920-932.
3. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
4. Pasqualucci L. The genetic basis of diffuse large B-cell lymphoma. Curr Opin Hematol 2013; 20: 336-344.
5. Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G et al. Burkitt's lymphoma. Lancet 2012; 379: 1234-1244.
6. Mann RB, Jaffe ES, Braylan RC, Nanba K, Frank MM, Ziegler JL et al. Non-endemic Burktt's lymphoma - A B-cell tumor related to germinal centers. N Engl J Med 1976; 195: 687-691.
7. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012; 490: 116-120.
8. Roberts CW, Orkin SH. The SWI/SNF complex-chromatin and cancer. Nat Rev Cancer 2004; 4: 133-142.
9. Green MR, Gentles AJ, Nair RV, Irish JM, Kihira S, Liu CL et al. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood 2013; 121: 1604-1611.
10. Green MR, Kihira S, Liu CL, Nair RV, Salari R, Gentles AJ et al. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc Natl Acad Sci USA 2015; 112: E1116-E1125.
11. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42: 181-185.
12. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011; 476: 298-303.
13. Morin RD, Mungall K, Pleasance E, Mungall AJ, Goya R, Huff RD et al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood 2013; 122: 1256-1265.
14. Okosun J, Bodor C, Wang J, Araf S, Yang CY, Pan C et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet 2014; 46: 176-181.
15. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011; 471: 189-195.
16. Pasqualucci L, Khiabanian H, Fangazio M, Vasishtha M, Messina M, Holmes AB et al. Genetics of follicular lymphoma transformation. Cell Rep 2014; 6: 130-140.
17. Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA 2013; 110: 1398-1403.
18. Love C, Sun Z, Jima D, Li G, Zhang J, Miles R et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 2012; 44: 1321-1325.
19. Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol 2005; 6: 838-849.
20. Black JC, Van Rechem C, Whetstine JR. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol Cell 2012; 48: 491-507.
21. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007; 7: 823-833.
22. Denissov S, Hofemeister H, Marks H, Kranz A, Ciotta G, Singh S et al. Mll2 is required for H3K4 trimethylation on bivalent promoters in embryonic stem cells, whereas Mll1 is redundant. Development 2014; 141: 526-537.
23. Ng SB, Bigham AW, Buckingham KJ, Hannibal MC, McMillin MJ, Gildersleeve HI et al. Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. Nat Genet 2010; 42: 790-793.
24. Guo C, Chang CC, Wortham M, Chen LH, Kernagis DN, Qin X et al. Global identification of MLL2-targeted loci reveals MLL2's role in diverse signaling pathways. Proc Natl Acad Sci USA 2012; 109: 17603-17608.
25. Schmitges FW, Prusty AB, Faty M, Stutzer A, Lingaraju GM, Aiwazian J et al. Histone methylation by PRC2 is inhibited by active chromatin marks. Mol Cell 2011; 42: 330-341.
26. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008; 105: 13520-13525.
27. Vieyra D, Loewith R, Scott M, Bonnefin P, Boisvert FM, Cheema P et al. Human ING1 proteins differentially regulate histone acetylation. J Biol Chem 2002; 277: 29832-29839.
28. Nourani A, Doyon Y, Utley RT, Allard S, Lane WS, Cote J. Role of an ING1 growth regulator in transcriptional activation and targeted histone acetylation by the NuA4 complex. Mol Cell Biol 2001; 21: 7629-7640.
29. Beguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 2013; 23: 677-692.
30. Kotake Y, Cao R, Viatour P, Sage J, Zhang Y, Xiong Y. pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene. Genes Dev 2007; 21: 49-54.
31. van Galen JC, Dukers DF, Giroth C, Sewalt RG, Otte AP, Meijer CJ et al. Distinct expression patterns of polycomb oncoproteins and their binding partners during the germinal center reaction. Eur J Immunol 2004; 34: 1870-1881.
32. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42: 722-726.
33. Ntziachristos P, Tsirigos A, Van Vlierberghe P, Nedjic J, Trimarchi T, Flaherty MS et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med 2012; 18: 298-301.
34. Bodor C, O'Riain C, Wrench D, Matthews J, Iyengar S, Tayyib H et al. EZH2 Y641 mutations in follicular lymphoma. Leukemia 2011; 25: 726-729.
35. McCabe MT, Graves AP, Ganji G, Diaz E, Halsey WS, Jiang Y et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci USA 2012; 109: 2989-2994.
36. Yap DB, Chu J, Berg T, Schapira M, Cheng SW, Moradian A et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011; 117: 2451-2459.
37. Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci USA 2010; 107: 20980-20985.
38. Lee JM, Lee JS, Kim H, Kim K, Park H, Kim JY et al. EZH2 generates a methyl degron that is recognized by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex. Mol Cell 2012; 48: 572-586.
39. Su IH, Dobenecker MW, Dickinson E, Oser M, Basavaraj A, Marqueron R et al. Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell 2005; 121: 425-436.
40. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012; 492: 108-112.
41. Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chemi Biol 2012; 8: 890-896.
42. Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci USA 2012; 109: 21360-21365.
43. Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. Oncogene 2004; 23: 4225-4231.
44. Xu W, Fukuyama T, Ney PA, Wang D, Rehg J, Boyd K et al. Global transcriptional coactivators CREB-binding protein and p300 are highly essential collectively but not individually in peripheral B cells. Blood 2006; 107: 4407-4416.
45. Petrij F, Giles RH, Dauwerse HG, Saris JJ, Hennekam RC, Masuno M et al. Rubinstein-Taybi syndrome caused by mutations in the transcriptional coactivator CBP. Nature 1995; 376: 348-351.
46. Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011; 471: 235-239.
47. Beresford GW, Boss JM. CIITA coordinates multiple histone acetylation modifications at the HLA-DRA promoter. Nat Immunol 2001; 2: 652-657.
48. Kretsovali A, Agalioti T, Spilianakis C, Tzortzakaki E, Merika M, Papamatheakis J. Involvement of CREB binding protein in expression of major histocompatibility complex class II genes via interaction with the class II transactivator. Mol Cell Biol 1998; 18: 6777-6783.
49. Fontes JD, Kanazawa S, Jean D, Peterlin BM. Interactions between the class II transactivator and CREB binding protein increase transcription of major histocompatibility complex class II genes. Mol Cell Biol 1999; 19: 941-947.
50. Ye BH, Lista F, Lo Coco F, Knowles DM, Offit K, Chaganti RS et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 1993; 262: 747-750.
51. Green MR, Vicente-Duenas C, Romero-Camarero I, Long Liu C, Dai B, Gonzalez-Herrero I et al. Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. Nat Commun 2014; 5: 3904.
52. Dhordain P, Lin RJ, Quief S, Lantoine D, Kerckaert JP, Evans RM et al. The LAZ3 (BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Nucleic Acids Res 1998; 26: 4645-4651.
53. Lemercier C, Brocard MP, Puvion-Dutilleul F, Kao HY, Albagli O, Khochbin S. Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor. J Biol Chem 2002; 277: 22045-22052.
54. Trinh DL, Scott DW, Morin RD, Mendez-Lago M, An J, Jones SJ et al. Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood 2013; 121: 3666-3674.
55. Srinivasan L, Sasaki Y, Calado DP, Zhang B, Paik JH, DePinho RA et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 2009; 139: 573-586.
56. Szydlowski M, Jablonska E, Juszczynski P. FOXO1 transcription factor: a critical effector of the PI3K-AKT axis in B-cell development. Int Rev Immunol 2014; 33: 146-157.
57. Matsuzaki H, Daitoku H, Hatta M, Aoyama H, Yoshimochi K, Fukamizu A. Acetylation of Foxo1 alters its DNA-binding ability and sensitivity to phosphorylation. Proc Natl Acad Sci USA 2005; 102: 11278-11283.
58. Liu Y, Hermanson M, Grander D, Merup M, Wu X, Heyman M et al. 13q deletions in lymphoid malignancies. Blood 1995; 86: 1911-1915.
59. Monti S, Chapuy B, Takeyama K, Rodig SJ, Hao Y, Yeda KT et al. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell 2012; 22: 359-372.
60. Wada M, Okamura T, Okada M, Teramura M, Masuda M, Motoji T et al. Frequent chromosome arm 13q deletion in aggressive non-Hodgkin's lymphoma. Leukemia 1999; 13: 792-798.
61. Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 1998; 391: 597-601.
62. Li H, Kaminski MS, Li Y, Yildiz M, Ouillette P, Jones S et al. Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. Blood 2014; 123: 1487-1498.
63. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA 2012; 109: 3879-3884.
64. McKinsey TA, Zhang CL, Olson EN. MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem Sci 2002; 27: 40-47.
65. Ogura M, Ando K, Suzuki T, Ishizawa K, Oh SY, Itoh K et al. A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol 2014; 165: 768-776.
66. Kirschbaum M, Frankel P, Popplewell L, Zain J, Delioukina M, Pullarkat V et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2011; 29: 1198-1203.
67. Fischle W, Wang Y, Allis CD. Histone and chromatin cross-talk. Curr Opin Cell Biol 2003; 15: 172-183.
68. Woodcock CL, Ghosh RP. Chromatin higher-order structure and dynamics. Cold Spring Harb Perspect Biol 2010; 2: a000596.
69. Dunaief JL, Strober BE, Guha S, Khavari PA, Alin K, Luban J et al. The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell 1994; 79: 119-130.
70. Wu RC, Wang TL, Shih Ie M. The emerging roles of ARID1A in tumor suppression. Cancer Biol Ther 2014; 15: 655-664.
71. Guan B, Gao M, Wu CH, Wang TL, Shih Ie M. Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions. Neoplasia 2012; 14: 986-993.
72. Luo B, Cheung HW, Subramanian A, Sharifnia T, Okamoto M, Yang X et al. Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci USA 2008; 105: 20380-20385.
73. Holley DW, Groh BS, Wozniak G, Donohoe DR, Sun W, Godfrey V et al. The BRG1 chromatin remodeler regulates widespread changes in gene expression and cell proliferation during B cell activation. J Cell Physiol 2014; 229: 44-52.
74. Helming KC, Wang X, Wilson BG, Vazquez F, Haswell JR, Manchester HE et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med 2014; 20: 251-254.
75. Hoffman GR, Rahal R, Buxton F, Xiang K, McAllister G, Frias E et al. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc Natl Acad Sci USA 2014; 111: 3128-3133.
76. Izzo A, Kamieniarz K, Schneider R. The histone H1 family: specific members, specific functions? Biol Chem 2008; 389: 333-343.
77. Bustin M, Catez F, Lim JH. The dynamics of histone H1 function in chromatin. Mol Cell 2005; 17: 617-620.
78. Fan Y, Nikitina T, Morin-Kensicki EM, Zhao J, Magnuson TR, Woodcock CL et al. H1 linker histones are essential for mouse development and affect nucleosome spacing in vivo. Mol Cell Biol 2003; 23: 4559-4572.
79. Fan Y, Nikitina T, Zhao J, Fleury TJ, Bhattacharyya R, Bouhassira EE et al. Histone H1 depletion in mammals alters global chromatin structure but causes specific changes in gene regulation. Cell 2005; 123: 1199-1212.
80. Fan Y, Sirotkin A, Russell RG, Ayala J, Skoultchi AI. Individual somatic H1 subtypes are dispensable for mouse development even in mice lacking the H1(0) replacement subtype. Mol Cell Biol 2001; 21: 7933-7943.
81. Yang P, Guo L, Duan ZJ, Tepper CG, Xue L, Chen X et al. Histone methyltransferase NSD2/MMSET mediates constitutive NF-kappaB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop. Mol Cell Biol 2012; 32: 3121-3131.
82. Martin C, Cao R, Zhang Y. Substrate preferences of the EZH2 histone methyltransferase complex. The J Biol Chem 2006; 281: 8365-8370.
83. van Haaften G, Dalgliesh GL, Davies H, Chen L, Bignell G, Greenman C et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 2009; 41: 521-523.
84. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012; 12: 335-348.
85. Jaffe JD, Wang Y, Chan HM, Zhang J, Huether R, Kryukov GV et al. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nat Genet 2013; 45: 1386-1391.